NEW YORK, NY--(Marketwired - April 11, 2014) - Plandaí Biotechnology (OTCQB: PLPL) has a deal in place to brand and market its future cannabis extracts under the Diego Pellicer Gold label, and it could be those extracts and the company's work with cannabinoids that help shape public opinion in favor of using the drug medicinally. A Pew Research Center survey released last week found that 75 percent of Americans say they feel the legal sale and use of marijuana is inevitable whether they support it or not. While support for marijuana grows, Plandaí and its extracts could go a long way toward changing the minds of the drug's opponents.
In the survey, 54 percent of respondents favored legalizing the use of marijuana which is a dramatic change from just 4 years ago when in the same survey, only 41 percent thought pot should be legal. Make no mistake about it attitudes are shifting in favor of marijuana in this country, and recent interest is likely due to CNN Chief Medical Correspondent Sanjay Gupta's "Weed" documentaries that are educating more Americans on the realities of cannabis. "Weed" documentaries can be seen commercial free at www.stockmarketmediagroup.com/media.
Dr.Gupta himself was once a staunch opponent of legalizing marijuana, but he has since become a strong advocate for the use of cannabis. In those documentaries, Dr. Gupta has highlighted just how powerful the use of cannabinoids can be as a treatment for such things as seizures, pain management, cancer and many others.
Plandaí produces highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, and will explore the use of both THC and cannabinoids to develop extracts and to pursue various pharmaceutical and nutraceutical applications. Dr. Gupta and a majority of Americans in general agree with Plandaí's CEO Roger Duffield who said, "The medicinal opportunities associated with phyto-cannabinoids are simply too great to ignore."
About Stock Market Media Group
SMMG is a Research and Content Development IR firm that offers a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí articles, reports and interviews by a third party who reserves the right to buy, sell or remain neutral on securities at any time before, during, or after the publication of this article. To date, SMMG has received total compensation of $40,640, for content related to Plandaí. For more information: www.stockmarketmediagroup.com/.